Please reload

Recent Posts

Non-Sintered Metal Oxide Nanocrystals

August 31, 2017

Please reload

Featured Posts

Label-Free, Targeted Treatment Against Metastatic Cancer for Recurrence-Free Survival

╪1,3Margo Waters, ╪1,3Juliane Hopf, 1,3Paul Helquist, 2Vincent Jo Davisson, and 1,3Prakash. D. Nallathamby

1University of Notre Dame, Notre Dame USA; 2Purdue University, Lafayette, USA; 3NDnano, Notre Dame, USA

╪ Equal contributors


The leading cause of fatalities in breast cancer is metastasis.1 To increase the success rate of metastasis-free survival, there is a need to tackle therapy-resistant metastatic forms of the disease with novel, patient-friendly, combinatorial treatment regimens. At present, doxorubicin (Dox) regimens are standard of care for tumor debulking but do not stop metastatic recurrence and present cardiotoxicity. Vacuolar ATPase (V-ATPase) H+ pump inhibitors (e.g., diphyllins) prevent metastasis, but the ubiquitous occurrence of this target raises concerns of off-target toxicity.2 A solution is targeted delivery to reduce off-target effects while also minimizing drug dose side-effects.3 So, here we present the successful demonstration of targeted combinatorial-delivery of V-ATPase inhibitors (Diph) and standard chemotherapeutics (Dox) to the MDAMB231 triple negative breast cancer metastatic cell model  (2D and 3D) with positive cell clearance and affirmative inhibition of cancer cell invasion. Our drug delivery system used a label-free magnetoelectric system.


Congratulations to Dr.



Hopf and undergraduate researcher Margo Waters for their contributions to these excellent results.


References : [1] Dubey, A.K., et al. Asian Pac J Cancer Prev 16, 4237-45 (2015). [2] McHenry, P. et al. J Cell Biochem 109, 634-42 (2010). [3] Huang, T. et al. Anal Chem 79, 7708-18 (2007).

Share on Facebook
Share on Twitter
Please reload

Follow Us
Please reload

Search By Tags
Please reload

  • LinkedIn Social Icon
  • Twitter Basic Square